• Revenue increased 53% to $8M
• Normalised EBITDA of $1.6M at 20% operating margin
• Profit after tax of $1.5 million

Resonance Health Limited (ASX: RHT) reported continued strong revenue growth and a return to profitability in its Appendix 4D and Half-Year Financial Report for the six-months ended 31 December 2025. Revenue increased 53% to $8M, driven by execution across the company's three business units: Resonance Clinical, TrialsWest, and Software-as-a-Medical Device (SaMD) Image Analysis Services. The company recorded a net profit after tax of $1.5M and continued to generate positive operating cash flow. Resonance Clinical progressed a $13.8M global major-pharma clinical trial services agreement, while TrialsWest expanded its patient reach and clinical trial service capability. The SaMD business secured new clinical trial service contracts and extensions, with the total forward order and tendered pipeline now exceeding $10M. The company also completed testing and validation of its new 'Bridge' automation technology and the extended proof-of-concept trial for its non-invasive MRI Liver Fibrosis SaMD. Resonance Health enters the second half of FY26 with continued delivery under global major pharmaceutical agreements, a record SaMD forward orders and bid-tender pipeline, and expanding and increasingly profitable TrialsWest operations.

Previously stated guidance of full year FY26 Revenue of $17M and EBITDA of $2M is maintained.

Resonance Health remains focused on disciplined growth and operational delivery, with near-term milestones in fibrosis SaMD development and workflow automation.